Celgene Corporation (CELG)
CELG Price and Sentiment
CELG Latest news
Entwistle & Cappucci LLP Files a Securities Class Action Complaint Against Bristol-Myers Squibb Company2021-10-06 18:44
NEW YORK--(BUSINESS WIRE)--ENTWISTLE & CAPPUCCI LLP FILES A SECURITIES CLASS ACTION COMPLAINT AGAINST BRISTOL-MYERS SQUIBB COMPANY
China's influence in the global pharmaceutical industry is on the rise
These value investments can generate above-average payouts for your portfolio. And they're trading at pretty fair prices.
These healthcare and retail giants have proven their resilience during a rough-and-tumble year.
These stocks are great anchors for any healthcare investor's portfolio.
Investors and analysts who questioned the wisdom of Bristol-Myers Squibb Co.’s (NYSE:BMY) purchase of Celgene last year for $74 billion might want to reconsider their opinion about the largest health care takeover in history.
Does Celgene (CELG) have what it takes to be a top stock pick for momentum investors? Let's find out.
Celgene (CELG) reported earnings 30 days ago. What's next for the stock?
Healthcare is hot, and these top healthcare stocks could be among the hottest of them all this year.